Blood Disorders Center At Seattle Children Hospital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

University of washingtonUnited statesFred hutchinson cancer research centerTovorafenib ojemdaPediatric brain tumor programBlood disorders center at seattle children hospitalUniversity of washington school medicineBlood disorders centerSeattle childrenWashington schoolFred hutchinson cancer research